Abstract: Methods, systems, and apparatuses are disclosed for radiation treatment of tumors based at least in part on patient-specific imaging information. The methods, systems and apparatuses include computer programs encoded on computer-readable media. The methods include acquiring imaging information relating to a target to be treated. The imaging information is non-anatomic imaging information relating to the target acquired from at least one imaging marker that reflects at least one of the metabolic, physiological and histological features of the target. The methods further include computing a radiation dose based at least on the imaging information.

Abstract: Methods, systems, and apparatuses are disclosed for radiation treatment of tumors based at least in part on patient-specific imaging information. The methods, systems and apparatuses include computer programs encoded on computer-readable media. The methods include acquiring imaging information relating to a target to be treated. The imaging information is non-anatomic imaging information relating to the target acquired from at least one imaging marker that reflects at least one of the metabolic, physiological and histological features of the target. The methods further include computing a radiation dose based at least on the imaging information.

Abstract: A primary sample holder for imaging, gross pathology, or histological correlations of a biological sample includes an enclosure having a first side wall, a second side wall, and a bottom wall; a plurality of slots provided at predetermined intervals along the first and second side walls; and a grid recessed within the bottom wall. The grid includes a hole bisected by a central panel and at least one axial panel that intersects the central panel along a length thereof. The biological sample received by the primary sample holder is configured to be aligned with the central panel of the grid to align the biological sample along an accepted internal orientation line (e.g., the anterior-posterior commissure line in the brain). The slots are configured to receive a cutting device to cut the biological sample into slices of uniform thickness containing a region of interest based on histological and imaging findings.

Abstract: A primary sample holder for imaging, gross pathology, or histological correlations of a biological sample includes an enclosure having a first side wall, a second side wall, and a bottom wall; a plurality of slots provided at predetermined intervals along the first and second side walls; and a grid recessed within the bottom wall. The grid includes a hole bisected by a central panel and at least one axial panel that intersects the central panel along a length thereof. The biological sample received by the primary sample holder is configured to be aligned with the central panel of the grid to align the biological sample along an accepted internal orientation line (e.g., the anterior-posterior commissure line in the brain). The slots are configured to receive a cutting device to cut the biological sample into slices of uniform thickness containing a region of interest based on histological and imaging findings.

Abstract: An electronic position guidance device is configured to attach to a medical device having a first end configured for percutaneous insertion and a second end configured to remain exterior to a patient's skin. The device includes an orientation attachment configured to detect an orientation and a position of the medical device, a processor configured to receive orientation and position information from the orientation attachment and determine a degree to which an actual insertion angle of the medical device deviates from a target angle and/or a degree to which an actual insertion depth of the medical device deviates from a target insertion depth, a display configured to visually convey to a user, in real-time via graphic, text and/or color, the orientation and the position of the medical device, and a speaker configured to audibly convey to the user, in real-time via sound, the orientation and the position of the medical device.

Abstract: Methods, systems, and apparatuses are disclosed for radiation treatment of tumors based at least in part on patient-specific imaging information. The methods, systems and apparatuses include computer programs encoded on computer-readable media. The methods include acquiring imaging information relating to a target to be treated. The imaging information is non-anatomic imaging information relating to the target acquired from at least one imaging marker that reflects at least one of the metabolic, physiological and histological features of the target. The methods further include computing a radiation dose based at least on the imaging information.

Abstract: An apparatus (10) for evaluating a liquid hydrocarbon to determine the propensity for coke formation comprising an injector (12), a supply of air (14) arranged to supply air to the injector (12) and a supply of liquid hydrocarbon (16) arranged to supply liquid hydrocarbon to the injector (12). The injector (12) is arranged to atomise the liquid hydrocarbon and to supply the air and atomised liquid hydrocarbon into a chamber (18) and the chamber (18) is arranged to supply atomised liquid hydrocarbon and air to a test pipe (20) and a heater (22) is arranged to heat the test pipe (20). The test pipe (20) is pivotably mounted on a frame (28) such that the orientation of the test pipe (20) relative to the frame (28) is variable. The apparatus (10) is able to simulate conditions within a vent pipe of a lubricant system of an aero gas turbine engine.

Abstract: An apparatus (10) for evaluating a liquid hydrocarbon to determine the propensity for coke formation comprising an injector (12), a supply of air (14) arranged to supply air to the injector (12) and a supply of liquid hydrocarbon (16) arranged to supply liquid hydrocarbon to the injector (12). The injector (12) is arranged to atomise the liquid hydrocarbon and to supply the air and atomised liquid hydrocarbon into a chamber (18) and the chamber (18) is arranged to supply atomised liquid hydrocarbon and air to a test pipe (20) and a heater (22) is arranged to heat the test pipe (20). The test pipe (20) is pivotably mounted on a frame (28) such that the orientation of the test pipe (20) relative to the frame (28) is variable. The apparatus (10) is able to simulate conditions within a vent pipe of a lubricant system of an aero gas turbine engine.

Abstract: A fluid monitoring arrangement 1 for an engine is operated in accordance with a method whereby nuclear magnetic resonance (NMR) interrogation of the fluid flow 3 it is possible to determine whether appropriate fluids and additives are being utilised as well as whether potential detrimental actions occur such as engine wear and carbonisation through particulate components within the flow 3. Generally, an expected signal response from the fluid flow 3 is determined and the actual signal response compared in a comparator 8 with that expected signal response. Divergence in the actual signal response and in particular with regard to its profile is identified and an indication provided in a display 10 with regard to the potential coolant of such divergence. Normally, a reference library 11 is provided of expected signal responses for comparison in the comparator with the actual signal responses.

Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.

Abstract: The present invention provides BRACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.

Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use and preparation, and intermediates for their preparation.

Abstract: The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.

Abstract: A fluid monitoring arrangement 1 for an engine is operated in accordance with a method whereby nuclear magnetic resonance (NMR) interrogation of the fluid flow 3 it is possible to determine whether appropriate fluids and additives are being utilised as well as whether potential detrimental actions occur such as engine wear and carbonisation through particulate components within the flow 3. Generally, an expected signal response from the fluid flow 3 is determined and the actual signal response compared in a comparator 8 with that expected signal response. Divergence in the actual signal response and in particular with regard to its profile is identified and an indication provided in a display 10 with regard to the potential coolant of such divergence. Normally, a reference library 11 is provided of expected signal responses for comparison in the comparator with the actual signal responses.

Abstract: A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: A method of making HIV protease inhibitors of general formula (1): 1

Abstract: Compounds useful as intermediates in the preparation of HIV protease inhibitors.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.